A method of treating benign prostatic hyperplasia

 

(57) Abstract:

The invention relates to medicine, in particular to urology, and can be used for the treatment of benign prostatic hyperplasia. Standard solution luciferan in an amount of 5 ml is administered rectally in the beginning of the treatment and conduct phonophoresis. Treatment once a day with an interval of 24 h treatment 10-12 sessions lasting 10 min each. The method allows to stimulate local tissue immunity of the prostate due to the normalization of homeostasis in the body. This increases the efficiency of treatment of the disease.

The invention relates to medicine, in particular to urology, and can be used in non-surgical treatment of benign prostatic hyperplasia in hospitals, clinics and sanatoriums.

Benign prostatic hyperplasia (BPH) is one of the most common urological diseases. Held in Russia epidemiological studies (Benign prostatic hyperplasia // Ed. by N. N. Lopatkina. - M.: Nauka, 1999) indicate an increase in the hours of the Ziya prostate cancer is one of the most pressing problems of urology.

Until recently, the most common treatment for BPH was open operation - adenomectomy. In connection with increase of the total number of patients suffering from this disease, and in particular with the increase in the share of high postoperative risk patients with complex comorbidities, high postoperative mortality (2-3%) and a significant number (up to 12-23%) postoperative complications (Trapeznikov M. F. , Bazayev centuries Classification methods for the treatment of benign prostatic hyperplasia. - In the book: Benign prostatic hyperplasia /Ed. by N. N. Lopatkina. - M.: Nauka, 1999), in the last two decades there has been a shift of emphasis from traditional surgical treatments for BPH to a wide range of non-surgical methods.

Existing non-operative methods in recent years become increasingly shift towards the use of high energy, determining, on the one hand, greater efficiency effects on the prostate gland, with the other becoming more and more dangerous for the patient, causing sometimes severe complications. Such methods today include thermal methods, in particular, thermotherapy and method for the treatment of benign prostatic hyperplasia. - In the book: Benign prostatic hyperplasia /Ed. by N. N. Lopatkina. - M.: Nauka, 1999) suggests that the only accepted pills drug able to reduce the volume of the prostate in BPH, is finasteride (proscar).

Clinically significant improvement in symptoms and minor (14-18%) volume reduction of the prostate can occur in approximately 30-40% of patients, with most of them it is not earlier than in 6 to 12 months after starting treatment with finasteride (Sivkov Century A. Medical therapy of benign prostatic hyperplasia. - In the book: Benign prostatic hyperplasia /Ed. by N. N. Lopatkina. - M.: Nauka, 1999). In addition, the use of finasteride may be accompanied by adverse effects and complications. All this, and the need for long (2.5 to 4 years) of continuous administration of the drug and its very high cost, do not sufficiently effective treatment of BPH.

Conducted research on the medical-scientific and patent literature identified various methods used in the treatment of BPH.

So, the author's certificate of the USSR N 10299559 published in B. I. N 27, 1983 , protected FPIC

In the author's certificate of the USSR N 1146066 published in B. I. N 11, 1985 , describes a "Method of treatment of patients with prostatic hypertrophy," which includes the impact on the hypothalamic-pituitary region of the patient UHF field capacity 5-30 watts.

In the patent of Russian Federation N 2125425 published in B. I. N 3, 1999, describes a "Method for treatment of benign prostatic hyperplasia", which consists in conducting thermotherapy in different temperature regimes depending on the indications.

RF patent N 2144370 published in B. I. No. 2, 2000, protected "Homeopathic medicinal product for the treatment of hypertrophy of the prostate".

The disadvantage of the above methods of treatment of BPH is their low efficiency, lack of a stable clinical effect and the availability of various complications in their implementation.

The closest in technical essence and selected as the prototype is protected by copyright certificates of the USSR N 1014576 (IPC A 61 H 23/00, publ. in B. I. N 16, 1983) "Method of treatment of patients with prostate cancer". It is done by transrectal of phonophoresis oksiprogesterona kapronata.

This method has the following negosudarstvennoe to change the volume of the prostate, act to improve urination and has no lasting clinical effect. As a consequence, almost all patients treated with oksiprogesterona kapronat, were soon after treatment subjected to surgery (Tiktinsky O. L., Novikov, I. F., Mikhailichenko centuries diseases of the genital organs in men. - M.: Medicine, 1985).

Secondly, the use of oksiprogesterona kapronata as other gestagens can lead to side reactions in men, the most frequent of which are decreased libido, impotence, hot flashes, gynecomastia, and deterioration of cardiac activity, and with long-term use of this drug may hepatotoxic effects (Benign prostatic hyperplasia // Ed. by N. N. Lopatkina. - M.: Nauka, 1999).

The aim of the present invention is to reduce the volume of the prostate, reducing side effects and the achievement of prostatic hyperplasia.

This objective is achieved in that the treatment of patients with BPH performed by transrectal medical phonophoresis, and as the medicinal product applied lacapere, standard solution which 5,0 ostavlaet 10-12 sessions lasting 10 minutes each.

Theoretical background of the claimed invention is to evaluate the uniqueness of the role of immune status as an important pathogenic component in the development of BPH and its treatment by introducing into the prostate gland immunomodulator - lacenterra.

The result is achieved that intraprostatically introduction lacenterra by transrectal of phonophoresis causes stimulation of the local tissue immunity of the prostate gland, and, at the same time, local stimulation system of natural immunity (NK-cells and T-lymphocytic link), aimed at restoring the structural homeostasis of the body affected hyperplastic process.

Lacapere activates the immune system, leads to an increase in NK-cell component, responsible for the recognition of transformed cells, tissues and destruction of the latter together with T-cell link. It enhances phagocytosis activates stem cells in the bone marrow, T-lymphocytes and macrophages, normalizes the balance between subpopulations T-helmerich and T-suppressor cells and has a strong stimulating effect on the activity of polymorphonuclear leukocytes. In addition erasektorile exposure to ultrasound has local anti-inflammatory, analgesic effect, increases local and General metabolic processes, improves trophic tissues and blood circulation in the prostate gland, promotes the resorption and softening of inflammatory infiltrates, scar elements. Thanks foretical the action of ultrasound, high therapeutic concentration of the drug in the prostate gland and its secretion lasts for 2-5 hours and only slightly reduced after 15 hours (Karpukhin such as Balneology and physiotherapy. - M., 1985, T. II, S. 261-283; ulasik C. C. Physico-pharmacological methods of treatment and prevention - Minsk, 1979). This phonophoresis of lacenterra not cause side effects.

The method is as follows.

After a preliminary examination of the patient, including medical history, clinical and laboratory studies, these immunological indexes in the number of transformed cells blood, ultrasound determining the size and volume of the prostate gland, the amount of residual urine determination uroflowmetric indicators and the evaluation of the function of the upper urinary tract, start treatment.

After emptying and cleansing enema to the patient, n is Feron 5,0 ml

Pre-lubricated with sterile glycerol with an area of radiating surface 1 cm2the emitter STI 0.88 to 1.03 diameter of certified domestic apparatus for ultrasonic therapy UST-1.03 injected into The rectum to a depth corresponding to the location of the prostate gland. Slightly press the emitter to serving the rectum posterior surface of the prostate and slowly, at a rate of 1-2 cm/s, perform its reciprocating movement along the surface of the prostate.

The effect on the prostate gland is carried out in a pulsed (pulse duration 4-10 MS) mode, frequency 879-881 kHz, intensity ultrasound of 0.2 - 0.4 W/cm2; the duration of any medical procedure - 10 minutes. Procedures carried out daily, once daily, with an interval of 24 hours. The course of treatment is 10 to 12 treatments.

Ultrasound intensity less than 0.2 W/cm2no significant therapeutic effect, and the application of ultrasound intensity more than 0.4 W/cm2may cause exacerbation of concomitant inflammatory process. The treatment course of 10-12 treatments is best, because umersanchez, and the increase in the number of procedures over 12 can cause significant negative shifts in the immune system.

Practical application of the proposed method is illustrated by examples from clinical practice.

Example 1.

Sick To Mr. P. A. has been treated in Rostov research center clinical sexologist and andrology (MCXA). Upon receipt complained of difficulty, weak stream of urine, feeling of incomplete emptying of the bladder, nycturia 4-5 times per night. Considers himself ill for four years, with the gradual development of symptoms. In the anamnesis - 2 myocardial infarction. In connection with coronary heart disease and postinfarction koronarokardioskleroze surgical treatment is possible only for health reasons. When entering a state of moderate severity, because of accompanying cardiovascular pathology.

Objectively: there is a dyspnea at rest, auscultation - heart sounds deaf, marked extrasystoles. AD - 165/75 mm RT. senior Bilirubin blood - 29 mg%, glucose - 7.4 mg%. Indicators of urea, creatinine is normal. In the analysis of urine - moderate leukocyturia (up to 20 per field). The secret of a prostate - leukocyte 0-1 in the field of view of the microflora in insignificant is 8.0 x 63,0 x 57,0 mm, the signs of benign prostatic. The amount of residual urine - 180 ml Uroflowmetric indicators: the volume of the bladder - 470,0 ml, maximum urine flow rate of 9.8 ml/s, the average rate of 4.3 ml/s the Level of PSA in the blood is 4.7 ng/ml Rectal - prostate spherical, without nodes, homogeneous, fugolastic consistency, almost painless.

The patient completed the treatment - completed 10 of therapeutic treatments offered by way of: transrectal phonophoresis of lacenterra, standard solution which 5,0 ml daily, once daily, with an interval of 24 hours, was administered rectally in the beginning of the treatments. The duration of one procedure - 10 minutes.

During treatment the patient improved urination, decreased frequency of nocturia. After treatment the patient was discharged in satisfactory condition. After 1 month examined. Since that time, the patient noted significant improvement in General condition. Decreased frequency of urination during the day, nocturia - unstable once during the night.

On ultrasound prostate size 49,0 x 54,0 x 49,0 mm, the amount of residual urine by 60.0 ml, uroflowmetric indicators: the volume of the bladder is x2">

During examination after 6 months: the patient's condition is satisfactory. Nocturia has practically disappeared. On ultrasound prostate size - 47.0 x 49,0 x 46,0 mm, the amount of residual urine - 32 ml, uroflowmetric indicators: the volume of the bladder - 420,0 ml, maximum urine flow rate is 18.4 ml/s, the average speed of 9.8 ml/s PSA Level is 2.4 ng/ml

Example 2.

Patient W s N. N. was on treatment in RNCSE. Complaints at admission for sluggish stream of urine, especially at night, nycturia 3-4 times per night, it is imperative that the urge to urinate, there is a time delay before starting urination. Among comorbidities - diabetes for 4 years, compensated, coronary heart disease. When receiving a satisfactory condition.

Objective: AD - 145/80 mm RT. Art. blood Glucose - 7.4 mg%. Indicators of urea, creatinine, bilirubin is normal. In the analysis of urine - tank weight - 1012, reasonable leukocyturia (up to 12 in the field of view). The secret of a prostate - leukocyte 6-10 in the field of view of the microflora in the small amount. Ultrasound of the kidneys - moderate diffuse changes on both sides.

Ultrasound of the prostate - size 54,0 x 53,0 x 51,0 mm, the signs of benign prostatic. The number is, the maximum urine flow rate and 12.4 ml/s, the average rate of 5.2 ml/s Rectal - prostate spherical, without nodes, homogeneous, fugolastic consistency, almost painless.

The patient completed the treatment - completed 10 of therapeutic treatments offered by way of: transrectal phonophoresis of lacenterra, standard solution which 5,0 ml daily, once daily, with an interval of 24 hours, was administered rectally in the beginning of the treatments. The duration of one procedure - 10 minutes.

During treatment the patient disappeared imperative urge to urinate, disappeared delay before starting urination, frequency, nocturia decreased to 1 time per night. After treatment the patient is entered. After 1 month examined. Since that time, the patient notes fickle single nycturia, improved stream and the pressure of the urine.

On ultrasound prostate size 50,0 x 49,0 x 48,0 mm, the amount of residual urine is not defined, uroflowmetric indicators: the volume of the bladder - 226,0 ml, maximum urine flow rate - of 16.3 ml/s, the average speed of 9.8 ml/s the Level of PSA - 1.8 ng/ml

During examination after 6 months: the patient satisfy romaticheskie indicators: the volume of the bladder - 218,0 ml, maximum urine flow rate is 19.2 ml/s, average speed and 10.8 ml/s PSA Level is 1.4 ng/ml

Thus, compared with the prototype of the proposed method for the treatment of benign prostatic hyperplasia reduces the volume of the prostate, reduce side effects and to achieve a stable clinical effect of treatment of benign prostatic hyperplasia.

A method for the treatment of benign hyperplasia of prostate cancer by transrectal medical phonophoresis, characterized in that the quality of drug use lacapere, standard solution which 5,0 ml daily, once daily, with an interval of 24 h administered rectally in the beginning of the treatments, the treatment course of 10-12 treatments, lasting 10 min each.

 

Same patents:

Rectal tool // 2152204
The invention relates to medicine and pharmaceutical industry and for the creation of new drugs used for the treatment of acute and chronic prostatitis

The invention relates to gynecology and is intended for the treatment of chronic oophoritis
The invention relates to medicine, dermatology

The invention relates to medical equipment, namely, devices for diagnostics and physiotherapy

The invention relates to medicine and can be used in surgery, traumatology and is intended for treatment of purulent-septic diseases and infected wounds
The invention relates to medicine and can be used in surgery when performing open heart surgery in patients with a high degree of activity of septic endocarditis
The invention relates to medicine, and is intended for the treatment of cancer
The invention relates to medicine, namely to pulmonology and Oncology

The invention relates to medicine and medical technology and relates to means and methods of therapeutic treatment of biological tissue ultrasonic fields

The invention relates to a device for punctuation ultrasound therapy (venopuncture)

The invention relates to medical equipment and can be used in ultrasound therapy
Remedy // 2172180
The invention relates to medicine, in particular to the pharmaceutical industry

The invention relates to medicine and can be used for the treatment of acute viral respiratory infections (ARI) in children
The invention relates to urology and is intended for the integrated treatment endourethral warts

The invention relates to medicine, in particular to combustology, and can be used for prevention of early sepsis in children tyazheloobozhzhennykh

The invention relates to medicine, in particular to immunology and neurology, and for the treatment of autoimmune diseases

The invention relates to medicine and for the development of new drugs for the treatment and prevention of viral diseases
The invention relates to medicine, namely to Oncology
The invention relates to pharmacology, specifically to the preparation interferonsource compositions, is able to maintain its biological activity, which can be used as drugs for intranasal use, for example for the preparation of drops in the nose
Up!